Beyond Blast Counts: How Menin Inhibition Redefines AML Immunophenotypes and Survival

MedXY Editorial Team•Mar 16, 2026•Hematology-Oncology

Menin inhibition with revumenib triggers a differentiation-driven antileukemic effect in KMT2A-rearranged and NPM1-mutated AML.
In a cohort of 48 patients, 52% of those treated with revumenib exhibited dynamic immunophenotypic changes, including lineage switches from stem-like to monocytic profiles.
Measurable residual disease (MRD) negativity by flow cytometry is a critical prognostic indicator, with MRD-negative responders achieving a median overall survival of 23.6 months.
The study highlights the necessity for adaptive flow cytometry protocols to track evolving leukemia-associated immunophenotypes (LAIPs) during targeted therapy.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Menin inhibition with revumenib triggers a differentiation-driven antileukemic effect in KMT2A-rearranged and NPM1-mutated AML.
In a cohort of 48 patients, 52% of those treated with revumenib exhibited dynamic immunophenotypic changes, including lineage switches from stem-like to monocytic profiles.
Measurable residual disease (MRD) negativity by flow cytometry is a critical prognostic indicator, with MRD-negative responders achieving a median overall survival of 23.6 months.
The study highlights the necessity for adaptive flow cytometry protocols to track evolving leukemia-associated immunophenotypes (LAIPs) during targeted therapy.